| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAM167A |
| Uniprot No | Q96KS9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-214aa |
| 氨基酸序列 | MSVPQIHVEEVGAEEGAGAAAPPDDHLRSLKALTEKLRLETRRPSYLEWQARLEEHTWPFPRPAAEPQASLEEGERGGQEPLLPLREAGQHPPSARSASQGARPLSTGKLEGFQSIDEAIAWLRKELTEMRLQDQQLARQLMRLRGDINKLKIEHTCRLHRRMLNDATYELEERDELADLFCDSPLASSFSLSTPLKLIGVTKMNINSRRFSLC |
| 预测分子量 | 28.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FAM167A重组蛋白的模拟参考文献及摘要概括(文献为虚拟示例，仅供参考)：
---
1. **文献名称**: "FAM167A重组蛋白通过调控MYC信号通路促进乳腺癌细胞增殖"
**作者**: Smith J, et al. (2015)
**摘要**: 本研究成功构建了FAM167A重组蛋白，并发现其过表达可激活MYC通路，显著增强乳腺癌MCF-7细胞的增殖能力，提示FAM167A可能作为潜在致癌因子参与肿瘤发展。
2. **文献名称**: "FAM167A重组蛋白在炎症反应中的功能及其与NF-κB通路的相互作用"
**作者**: Zhang L, et al. (2018)
**摘要**: 通过大肠杆菌系统表达并纯化FAM167A重组蛋白，实验证实其可诱导巨噬细胞中NF-κB信号活化，促进TNF-α和IL-6分泌，表明FAM167A可能在炎症性疾病中发挥调控作用。
3. **文献名称**: "FAM167A重组蛋白的结构解析及其与自闭症相关蛋白的相互作用"
**作者**: Chen X, et al. (2020)
**摘要**: 利用X射线晶体学解析了FAM167A重组蛋白的三维结构，并发现其与SHANK3蛋白存在直接结合，为理解FAM167A在神经发育障碍(如自闭症)中的分子机制提供了结构基础。
4. **文献名称**: "FAM167A重组蛋白作为新型生物标志物在自身免疫性疾病中的临床应用"
**作者**: Johnson R, et al. (2022)
**摘要**: 通过ELISA检测发现类风湿性关节炎患者血清中FAM167A重组蛋白水平显著升高，且与疾病活动度正相关，提示其可作为诊断或预后评估的潜在生物标志物。
---
**注**: 以上文献为示例性内容，实际研究中请通过PubMed、Google Scholar等平台检索真实发表的论文。
**Background of FAM167A Recombinant Protein**
FAM167A (Family with Sequence Similarity 167 Member A), also known as C8orf76. is a gene located on chromosome 8 (8q24.3) encoding a protein whose precise biological function remains incompletely characterized. Studies suggest it may play roles in cellular processes such as proliferation, differentiation, and transcriptional regulation. The FAM167A protein is ubiquitously expressed across tissues, with higher levels observed in the brain, testis, and certain cancer cells, implying potential tissue-specific or disease-related functions.
Emerging evidence links FAM167A to human diseases. For instance, it has been identified as a candidate gene in neuropsychiatric disorders, including schizophrenia and autism spectrum disorders, through genetic association studies. Additionally, FAM167A exhibits co-amplification and co-expression with the MYC oncogene in cancers, suggesting a possible synergistic role in tumorigenesis, particularly in prostate and lung cancers. Its interaction with MYC and localization to nuclear speckles further hints at involvement in transcriptional or post-transcriptional regulation.
Recombinant FAM167A protein is engineered for in vitro studies to elucidate its molecular interactions, post-translational modifications, and pathways. Its production typically involves heterologous expression systems (e.g., E. coli or mammalian cells) to ensure proper folding and functionality. Researchers utilize this tool to investigate FAM167A's binding partners, such as proposed interactions with RNA-binding proteins, and its impact on cellular phenotypes like apoptosis or cell cycle progression.
Despite progress, FAM167A's mechanistic contributions to health and disease remain enigmatic. Recent studies also highlight its potential association with primary familial brain calcification (PFBC), though validation is ongoing. The development of recombinant FAM167A protein continues to support efforts to unravel its biological significance and therapeutic potential in diverse pathologies.
×
